Pregabalin Sandoz (pregabalin)
- Region
- 🇪🇺 EU
- Active substance
- pregabalin
- Company
- Sandoz GmbH
- Status
- Authorised
- Therapeutic area
- Anxiety Disorders; Neuralgia; Epilepsy
- CHMP opinion
- Thu 23 Apr 2015
- EU approval
- Fri 19 Jun 2015
- Designations
- Generic
- Application
- EMEA/H/C/004010
- ATC
- N02BF02
- Official record
- www.ema.europa.eu
Indication
Neuropathic pain Pregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults. Epilepsy Pregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised Anxiety Disorder Pregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Pregabalin Viatris (previously Pregabalin Mylan) Authorised · Viatris Limited
- 🇪🇺 Lyrica Authorised · Viatris EESV
- 🇪🇺 Pregabalin Viatris Pharma (previously Pregabalin Pfizer) Authorised · Viatris Healthcare Limited
- 🇪🇺 Pregabalin Zentiva Authorised · Zentiva k.s.
- 🇪🇺 Pregabalin Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Pregabalin Sandoz GmbH Withdrawn · Sandoz GmbH
- 🇪🇺 Pregabalin Zentiva k.s. Withdrawn · Zentiva k.s.
- 🇪🇺 Pregabalin Mylan Pharma Withdrawn · Mylan S.A.S.
Follow Pregabalin Sandoz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.